Intensity Therapeutics Inc. (INTS) Company Profile and Analysis

Introduction

Intensity Therapeutics Inc. (NASDAQ: INTS) is a clinical-stage biotechnology company headquartered in Westport, Connecticut. The company develops intratumoral therapies designed to treat solid tumors and activate systemic immune responses. Its lead product candidate, INT230-6, leverages the proprietary DfuseRx™ platform to improve drug diffusion within tumors and induce T-cell responses against cancer.

Corporate Structure

Employee Count: 2–10 (LinkedIn)

Leadership Team:

• Lew H. Bender, Founder & CEO
  28 years in biopharmaceutical leadership; former CEO of Interleukin Genetics; held senior roles at Emisphere Technologies.
• Joseph Talamo, Chief Financial Officer
  25 years in financial leadership; former CFO of HiberCell and Caladrius Biosciences; CPA (NY).
• James M. Ahlers, Executive Vice President
  25 years in life-science finance; former CFO of Intarcia Therapeutics.
• John Wesolowski, Principal Accounting Officer & Controller
  Over 30 years in accounting; interim CFO since June 2023; former Director of Costing at Yale University.

Recent Developments and News

Date	Event
2025-06-11	Priced a public offering of 3,133,333 shares and warrants at $0.75; gross proceeds approximately $2.35 million (closing expected April 28).
2025-06-11	Filed free writing prospectuses under Securities Act Rules 163/433.
2025-05-29	INVINCIBLE-3 sarcoma Phase 3 study selected for presentation at ASCO 2025 Annual Meeting.
2025-05-13	Reported Q1 2025 financial results and corporate update.
2025-05-06	EMA authorized Phase 2 INVINCIBLE-4 trial in presurgical triple-negative breast cancer in France.
2025-04-25	Announced a public offering of 3,133,333 shares with Series B-1 and B-2 warrants; combined price $0.75.
2023-06-29	Initial public offering raised approximately $19.5 million; 3.9 million shares at $5.00 per share.

Financial and Strategic Analysis

Stock Performance (2025-06-12):

• Price: $0.3095
• Daily Change: -46.55%
• Volume: 2,807,579 shares
• 52-Week Range: $0.2845 – $5.10

Key Financial Metrics:

• Market Value (non-affiliates): $27.0 million (13,920,928 shares at $1.94 as of 2025-04-21)
• TTM Net Income: -$15.01 million
• Cash (most recent quarter): $0.93 million
• Total Debt/Equity: 39.22%
• Levered Free Cash Flow (TTM): -$7.06 million

Capital-Raising Activities:

• Rule 424(b)(5) prospectus filed on 2025-06-11.
• At-the-market (ATM) program amended on 2025-06-11, with a $15 million ceiling.
• ATM sales to date: 193,816 shares, with gross proceeds of $577,831.

Strategic Partnerships:

• Collaborations with Merck & Co. (pembrolizumab) and Bristol-Myers Squibb (ipilimumab).
• Cooperative Research and Development Agreement (CRADA) with NCI Vaccine Branch.
• Phase 2/3 collaboration with Swiss Group for Clinical Cancer Research (SAKK).

Market Position and Industry Context

Intensity Therapeutics operates in the intratumoral immunotherapy segment, targeting solid tumors through the direct injection of cytotoxic agents mixed with amphiphilic enhancers.

Pipeline Highlights:

• INT230-6
  • Phase 3 INVINCIBLE-3: metastatic sarcoma (overall survival endpoint).
  • Phase 2 INVINCIBLE-4: presurgical triple-negative breast cancer (pathological complete response endpoint).
• INT33X (Next-Generation): In preclinical to Phase 3 stages in multiple solid tumor types.

Regulatory Designations:

• Orphan Drug status for components used in the treatment of sarcoma.
• Fast Track designation for metastatic triple-negative breast cancer.

Intensity’s DfuseRx™ platform is designed to address tumor microenvironment barriers and differentiate its products from systemic immunotherapies while supporting immune activation.

tl;dr

• On June 11, 2025, INTS priced a public offering (3.13 million shares + warrants) targeting approximately $2.35 million in gross proceeds.
• Active clinical trials include Phase 3 INVINCIBLE-3 for sarcoma and Phase 2 INVINCIBLE-4 for presurgical triple-negative breast cancer; EMA authorized the latter in France.
• The ATM facility has been amended to allow up to $15 million in future share issuances; previous ATM sales generated approximately $0.58 million.
• Q1 2025 results indicate a net TTM loss of $15.0 million, cash of $0.93 million, and ongoing investment in research and development for INT230-6.
• Partnerships with Merck, Bristol-Myers Squibb, and SAKK support mid-stage clinical development.